Novartis discontinued a Phase 1 protein-based oncology candidate after it failed to produce tumor shrinkage in 30 patients with advanced solid tumors.
Longevity News
Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 pat...
Source: FierceBiotech - All • Published: 19 Feb 2026, 22:00
Continue exploring
Related longevity signals
Fight Aging!Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and HealthThis article previews research on using a bacterial enzyme to boost mitochondrial protein modification and overall cellular energy, framed as a potential metabolic-enhancing therapy. It invites readers curious about cross-species gene therapy approaches aimed at improving healthspan and age-related function.Nature - BiotechnologyContractile myografts confer systemic anti-aging benefitsSubcutaneous contractile muscle grafts: a research article examining a cell‑ and gene‑therapy approach that aims to influence systemic aging and metabolism.Nature - BiotechnologySpirulina‑mediated silver nanoparticles induce apoptosis and autophagy in Caco‑2 colorectal cancer cellsA study reports green synthesis of silver nanoparticles using a microalga extract and examines their effects on human colon cancer cells, focusing on cell death pathways.Fight Aging!Anti-Aging Medicine, a Small Specialty, Will Spread in Some Form to the Whole of MedicineAn analysis of how longevity-focused clinical practice and prevention strategies could expand from a niche specialty into mainstream medicine over time.